YCBD · cbdMD, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These and other factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that these financial statements are issued.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $20.93M | $19.19MG | $19.48M | $24.16M | $35.4M | $44.48M | $41.88M | $23.65M | $459.09K | $4.47M | $2.03M | |
| $15.09K | $34.31K | -$29.51K | $63.7K | $16.25K | -$28.93K | $39.88K | $75.07K | $0 | — | — | |
| $8.86M | $7.22M | $7.49M | $9.18M | $13.07M | $14.5M | $15.51M | $9.14M | $104.01K | $1.36M | $1.62M | |
| $12.07M | $11.97M | $12M | $14.98M | $22.34M | $29.99M | $26.37M | $14.51M | $355.08K | $3.12M | $413.13K | |
| — | 62.37% | 61.57% | 62.01% | 63.09% | 67.41% | 62.96% | 61.37% | 77.34% | 69.71% | 20.34% | |
| $765.09K | $765.08K | $697.51K | $1.4M | $884.38K | $0 | $1.18M | — | — | — | — | |
| — | — | — | — | — | $1.02M | $720.76K | $289.57K | $222.55K | $71.28K | $44.94K | |
| — | — | — | $0 | $602.09K | $0 | — | — | — | — | — | |
| $50.03M | — | — | — | — | $49.6M | $43.95M | $29.31M | $2.15M | $3.36M | $4.15M | |
| -$2.9M | -$2.16M | -$3.32M | -$22.49M | -$78.27M | -$19.62M | -$17.58M | -$14.8M | -$1.8M | -$1.36M | -$3.89M | |
| — | -11.27% | -17.02% | -93.1% | -221.07% | -44.1% | -41.98% | -62.56% | -391.44% | -30.42% | -191.39% | |
| — | — | — | — | — | -$18.6M | -$16.86M | -$14.51M | -$1.57M | -$1.29M | -$3.84M | |
| -$76.11K | — | — | — | — | — | — | — | $955 | $500.63K | $154.98K | |
| — | — | — | $0 | $239.25K | $29.48K | — | — | — | — | — | |
| -$2.89M | -$2.04M | -$3.7M | -$22.94M | -$70.08M | -$24.29M | $11.31M | -$47.79M | -$1.8M | — | — | |
| — | $0 | $0 | $0 | $0 | -$895K | $1.35M | -$2.36M | $0 | $25K | $8000 | |
| -$2.89M | -$2.04M | -$3.7M | -$22.94M | -$70.08M | -$23.39M | $12.6M | -$51.36M | $62.83K | -$1.39M | -$3.9M | |
| — | -10.63% | -18.99% | -94.96% | -197.96% | -52.6% | 30.09% | -217.14% | 13.69% | -30.98% | -191.79% | |
| -$3.08M | -$4.38M | -$7.7M | -$26.94M | -$74.09M | -$25.95M | $12.24M | -$50.43M | -$412.08K | -$1.74M | -$3.36M | |
| — | -$4.37M | -$7.71M | -$26.94M | -$74.09M | -$25.95M | $12.6M | -$51.36M | -$2.45M | -$1.39M | — | |
| USD/shares | — | -$1.09 | -$14.29 | -$106.56 | -$446.40 | -$169.20 | $100.80 | -$1,015.20 | -$18.00 | — | — |
| USD/shares | — | -$1.09 | -$14.29 | -$106.56 | -$446.40 | -$169.20 | $100.80 | $0.00 | $0.00 | — | — |
| shares | — | 4.02M | 539.07K | 252.79K | 165.97K | 152.61K | 122.61K | 49.69K | 21.51K | 12.57K | 8278.3972 |
| shares | — | 4.02M | 539.07K | 252.79K | 165.97K | 152.61K | 125.48K | 49.69K | 21.53K | 12.57K | 8278.3972 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2021: $2.92M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 31 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| E-Commerce Sales | $32,907,956 | $30,456,496 |
| Wholesale Sales | $11,572,807 | $11,377,238 |